tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

FHTX Stock Latest News

Foghorn Therapeutics Unveils Strategic Advancements with Lilly
Company AnnouncementsFoghorn Therapeutics Unveils Strategic Advancements with Lilly
17h ago
8K
FHTX
Foghorn Therapeutics initiated with a Buy at Guggenheim
PremiumThe Fly
Foghorn Therapeutics initiated with a Buy at Guggenheim
1d ago
FHTX
Foghorn Therapeutics Reports Q3 2025 Financial Results
PremiumCompany Announcements
Foghorn Therapeutics Reports Q3 2025 Financial Results
2d ago
FHTX
Foghorn Therapeutics: Promising Pipeline and Strategic Collaborations Drive Buy Rating
PremiumRatings
Foghorn Therapeutics: Promising Pipeline and Strategic Collaborations Drive Buy Rating
3d ago
FHTX
Foghorn Therapeutics CFO Kristian Humer Resigns
PremiumCompany Announcements
Foghorn Therapeutics CFO Kristian Humer Resigns
3d ago
8K
FHTX
Foghorn Therapeutics reports Q3 EPS (25c), consensus (30c)
PremiumThe FlyFoghorn Therapeutics reports Q3 EPS (25c), consensus (30c)
3d ago
FHTX
Foghorn Therapeutics: Promising Advancements in ARID1B-Degrader Program and Strategic Focus Justify Buy Rating
Premium
Ratings
Foghorn Therapeutics: Promising Advancements in ARID1B-Degrader Program and Strategic Focus Justify Buy Rating
5d ago
FHTX
Foghorn Therapeutics: Advancements in Protein Degrader Programs and Strategic Partnerships Drive Buy Rating
Premium
Ratings
Foghorn Therapeutics: Advancements in Protein Degrader Programs and Strategic Partnerships Drive Buy Rating
8d ago
FHTX
Foghorn Therapeutics Announces Key Pipeline Updates
PremiumCompany Announcements
Foghorn Therapeutics Announces Key Pipeline Updates
9d ago
8K
FHTX
Foghorn announces updates for Selective ARID1B, Selective CBP, Selective EP300
PremiumThe Fly
Foghorn announces updates for Selective ARID1B, Selective CBP, Selective EP300
9d ago
FHTX
Foghorn Therapeutics announces progress for Selective ARID1B degrader program
PremiumThe Fly
Foghorn Therapeutics announces progress for Selective ARID1B degrader program
23d ago
FHTX
Foghorn Therapeutics transferred with Buy rating at B. Riley
PremiumThe Fly
Foghorn Therapeutics transferred with Buy rating at B. Riley
2M ago
FHTX
Foghorn Therapeutics Advances in Precision Therapeutics
PremiumCompany AnnouncementsFoghorn Therapeutics Advances in Precision Therapeutics
2M ago
8K
FHTX
Buy Rating for Foghorn Therapeutics: Promising Potential of Lead Candidate FHD-909 in Targeting SMARCA4-Mutated Cancers
Premium
Ratings
Buy Rating for Foghorn Therapeutics: Promising Potential of Lead Candidate FHD-909 in Targeting SMARCA4-Mutated Cancers
3M ago
FHTX
Foghorn Therapeutics Reports Q2 2025 Financial Results
Premium
Company Announcements
Foghorn Therapeutics Reports Q2 2025 Financial Results
3M ago
FHTX
Foghorn Therapeutics management to meet virtually with B. Riley
PremiumThe Fly
Foghorn Therapeutics management to meet virtually with B. Riley
3M ago
FHTX
Foghorn Therapeutics Reports Q2 2025 Financial Update
PremiumCompany Announcements
Foghorn Therapeutics Reports Q2 2025 Financial Update
3M ago
8K
FHTX
Foghorn Therapeutics reports Q2 EPS (28c), consensus (32c)
PremiumThe Fly
Foghorn Therapeutics reports Q2 EPS (28c), consensus (32c)
3M ago
FHTX
Foghorn Therapeutics Faces Significant Business Risk: Potential Impact on Operations and Investor Confidence
PremiumCompany Announcements
Foghorn Therapeutics Faces Significant Business Risk: Potential Impact on Operations and Investor Confidence
3M ago
FHTX
Foghorn Therapeutics Signs New Lease Agreement
PremiumCompany AnnouncementsFoghorn Therapeutics Signs New Lease Agreement
4M ago
8K
FHTX
Foghorn Therapeutics Holds Successful Annual Meeting
Premium
Company Announcements
Foghorn Therapeutics Holds Successful Annual Meeting
5M ago
8K
FHTX
Foghorn Therapeutics Reports Q1 2025 Financial Results
Premium
Company Announcements
Foghorn Therapeutics Reports Q1 2025 Financial Results
6M ago
FHTX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >